林业发展局核准新的癌症药物Ziishera用于血汗癌,标志着Zymeworks首次获得林业发展局的批准。 FDA approves new cancer drug Ziihera for biliary tract cancer, marking Zymeworks' first FDA approval.
美国食品和药物管理局已对Zihera给予加速批准, 这是一种由温哥华生物技术公司Zymeworks和Jazz Pharmaceuticals开发的新型癌症药物, 用于治疗胆道癌症. The FDA has granted accelerated approval to Ziihera, a new cancer drug developed by Vancouver-based biotech company Zymeworks and Jazz Pharmaceuticals, for treating biliary tract cancer. 这标志着Zymeworks 首次经FDA批准的治疗, 验证了他们创新的Azytrical双分平台技术。 This marks Zymeworks' first FDA-approved therapy, validating their innovative Azymetric bispecific platform technology. 该药物可产生超过10亿美元的里程碑付款,显示52%的客观答复率,中位数持续14.9个月。 The drug, which could generate over $1 billion in milestone payments, shows a 52% objective response rate with a median duration of 14.9 months.